BIO-TECHNE CORP's ticker is TECH and the CUSIP is 09073M104. A total of 549 filers reported holding BIO-TECHNE CORP in Q1 2022. The put-call ratio across all filers is 0.27 and the average weighting 0.2%.
About BIO-TECHNE CORP
Bio-Techne Corp is a leading provider of innovative life science research tools and diagnostic solutions. The company is headquartered in Minneapolis, Minnesota, and has operations in over 50 countries worldwide. Bio-Techne's products and services are used by researchers and clinicians in a wide range of fields, including cancer research, stem cell research, and immunology.
Bio-Techne's success is due in large part to its commitment to innovation and customer service. The company invests heavily in research and development, and has a team of over 1,000 scientists working to develop new products and technologies. Bio-Techne also has a strong focus on customer service, with a dedicated team of technical support specialists available to assist customers with any questions or issues they may have.
In addition to its research tools and diagnostic solutions, Bio-Techne also has a growing portfolio of clinical diagnostic products. The company's Exosome Diagnostics subsidiary is a leader in the development of liquid biopsy tests for cancer diagnosis and monitoring.
Bio-Techne's leadership team is comprised of experienced executives with a track record of success in the life sciences industry. Charles Kummeth, the company's CEO, has been with Bio-Techne since 2013 and has overseen significant growth and expansion during his tenure.
Overall, Bio-Techne is a company with a strong reputation for innovation, customer service, and leadership in the life sciences industry. With a growing portfolio of products and services, the company is well-positioned for continued success in the years to come.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $41,731,091 | +1.7% | 613,061 | +22.0% | 3.90% | +4.4% |
| Q2 2023 | $41,014,775 | +10.3% | 502,447 | +0.3% | 3.74% | +5.0% |
| Q1 2023 | $37,173,549 | -4.2% | 501,059 | +7.0% | 3.56% | -14.0% |
| Q4 2022 | $38,816,541 | +14.2% | 468,346 | +291.4% | 4.14% | +6.8% |
| Q3 2022 | $33,987,000 | +0.7% | 119,671 | +22.9% | 3.88% | +7.5% |
| Q2 2022 | $33,757,000 | -29.1% | 97,382 | -11.4% | 3.61% | -11.8% |
| Q1 2022 | $47,608,000 | -24.4% | 109,939 | -9.7% | 4.09% | -16.3% |
| Q4 2021 | $62,951,000 | +7.4% | 121,682 | +0.6% | 4.89% | +4.0% |
| Q3 2021 | $58,633,000 | +2.4% | 120,999 | -4.9% | 4.70% | +5.2% |
| Q2 2021 | $57,281,000 | +17.4% | 127,217 | -0.4% | 4.47% | +8.0% |
| Q1 2021 | $48,805,000 | +10.7% | 127,785 | -8.0% | 4.14% | +2.7% |
| Q4 2020 | $44,096,000 | +28.4% | 138,864 | +0.1% | 4.03% | +16.4% |
| Q3 2020 | $34,349,000 | -20.8% | 138,657 | -15.6% | 3.46% | -31.9% |
| Q2 2020 | $43,390,000 | +30.4% | 164,311 | -6.4% | 5.08% | +13.9% |
| Q1 2020 | $33,276,000 | -12.9% | 175,490 | +0.8% | 4.46% | +5.2% |
| Q4 2019 | $38,205,000 | +14.4% | 174,047 | +2.0% | 4.24% | +4.1% |
| Q3 2019 | $33,404,000 | -3.9% | 170,716 | +2.4% | 4.07% | -7.6% |
| Q2 2019 | $34,764,000 | +8.4% | 166,740 | +3.3% | 4.41% | -1.6% |
| Q1 2019 | $32,063,000 | +39.6% | 161,488 | +1.8% | 4.48% | +18.2% |
| Q4 2018 | $22,965,000 | -28.6% | 158,686 | +0.7% | 3.79% | -20.5% |
| Q3 2018 | $32,159,000 | +40.2% | 157,557 | +1.7% | 4.77% | +31.4% |
| Q2 2018 | $22,932,000 | +0.6% | 154,996 | +2.7% | 3.63% | -3.1% |
| Q1 2018 | $22,799,000 | – | 150,946 | – | 3.74% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Ownership Capital B.V. | 972,263 | $308,742,000 | 4.35% |
| Sandhill Capital Partners LLC | 138,864 | $44,096,000 | 4.03% |
| STONE RUN CAPITAL, LLC | 27,350 | $8,685,000 | 3.45% |
| DF DENT & CO INC | 925,823 | $293,995,000 | 3.42% |
| Brown Capital Management | 1,498,233 | $475,764,000 | 3.29% |
| MAIRS & POWER INC | 848,081 | $269,308,000 | 2.99% |
| Summit Creek Advisors LLC | 64,179 | $20,380,000 | 2.62% |
| GENEVA CAPITAL MANAGEMENT LLC | 402,958 | $127,959,000 | 2.17% |
| Aristotle Atlantic Partners, LLC | 86,993 | $27,625,000 | 2.13% |
| CROWN ADVISORS MANAGEMENT, INC. | 8,000 | $2,540,000 | 1.82% |